<DOC>
	<DOC>NCT01079130</DOC>
	<brief_summary>This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol</brief_summary>
	<brief_title>Efficacy and Safety of Different Doses of Indacaterol</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Patients with a diagnosis of asthma, and: 1. Receiving daily treatment with inhaled corticosteroid in a regimen that has been stable for at least a month prior to screening 2. Prebronchodilator forced expiratory volume in 1 second (FEV1) at screening ≥50 and ≤90% of predicted normal 3. An increase of ≥12% and ≥200 mL in FEV1 over prebronchodilator value within 30 minutes after inhaling albuterol Smoking history &gt;10 packyears Patients with a diagnosis of chronic obstructive pulmonary disease (COPD) Patients with seasonal allergy whose asthma is likely to deteriorate during the study period Patients who have experienced a severe asthma attack/exacerbation requiring hospitalization in the 6 months prior to screening Patients who have had an intubation for a severe asthma exacerbation Patients who have had an emergency room visit for an asthma attack/asthma exacerbation within 6 weeks prior to screening Patients who have had a respiratory tract infection within 6 weeks prior to screening Patients with concomitant pulmonary disease Patients with diabetes Type I or uncontrolled diabetes Type II Any patient with lung cancer or a history of lung cancer Patients with a history of certain cardiovascular comorbid conditions Patients who have ever received or are currently receiving omalizumab or chronic oral corticosteroid therapy Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Indacaterol</keyword>
	<keyword>asthma</keyword>
	<keyword>salmeterol</keyword>
</DOC>